Skip to Main Content

Author Details

Tim Dudderidge
University Hospital Southampton NHS Foundation Trust
2002
70
23
PMIDPaper TitleJournal TitlePublished Year
37778954The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.Eur Urol2024
36681537Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605].Eur Urol2023
37656223Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.J Med Econ2023
37385981External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.BJU Int2023
37014172Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience.J Urol2023
36653670Landmarks in the evolution of prostate biopsy.Nat Rev Urol2023
36511804Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.Radiology2023
35300937Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.Eur Urol Focus2022
35370021Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.Eur Urol2022
35123819Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.Eur Urol2022
31590961Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer.Eur Urol Focus2021
33504940Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study.Prostate Cancer Prostatic Dis2021
33632752Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial.BMJ Open2021
34977691A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.Eur Urol Open Sci2021
34407860Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study.Trials2021
34678156A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.Lancet Oncol2021
34794989Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study.BMJ Open2021
33934114Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control.Prostate Cancer Prostatic Dis2021
34318981Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.BJU Int2021
34139356PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study.Contemp Clin Trials2021
33051065False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.Eur Urol2021
32638084Focal HIFU therapy for anterior compared to posterior prostate cancer lesions.World J Urol2021
32745350Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.BJU Int2021
31307961A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.Eur Urol Oncol2020
31928408Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.J Urol2020
33057024A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists.Sci Rep2020
32676440Focal therapy, time to join the multi-disciplinary team discussion?Transl Androl Urol2020
32312543Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study.Eur Urol2020
32370911What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort.Eur Urol2020
32253928An Exploratory Study of Dose Escalation <i>vs</i> Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer.J Endourol2020
32314931Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.J Urol2020
30638633Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.Eur Urol2019
31537406Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.Eur Urol2019
30912958Establishing MRI-guided prostate intervention at a UK Centre.Br J Radiol2019
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29888845Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer.BJU Int2018
29960750A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.Eur Urol2018
30040065Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.Health Technol Assess2018
30264692Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT.Health Technol Assess2018
28815981Positive messages for bladder cancer management in negative sentinel lymph node study.BJU Int2017
28945760Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.PLoS Genet2017
26709240The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review.BJU Int2016
24913090Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion.Eur J Surg Oncol2015
26018901Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
25730763Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.Nat Genet2015
25510570Retroperitoneal lymph node dissection (RPLND) - open surgery's next challenger is ready to enter the ring.BJU Int2015
24467630Evolution of the Southampton Enhanced Recovery Programme for radical cystectomy and the aggregation of marginal gains.BJU Int2014
27637531Robot-assisted management of Zinner's syndrome: report of seminal vesicle sparing technique and review of literature.J Robot Surg2014
23065704A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.Hum Mol Genet2013
23535732Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Nat Genet2013
  • 1 - 50 of 70

Recommended Authors

Mayo Clinic
Career Start Year 2017
Number of shared co-authors 1
National Cancer Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 1
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Career Start Year 2012
Number of shared co-authors 2
University of North Carolina School of Medicine
Career Start Year 2012
Number of shared co-authors 1
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 1
university of california san diego School of Medicine
Career Start Year 2011
Number of shared co-authors 0
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 0
University of Texas Health San Antonio
Career Start Year 2008
Number of shared co-authors 2
University of Alberta
Career Start Year 2007
Number of shared co-authors 1
University of Oxford
Career Start Year 2007
Number of shared co-authors 30
University of California San Diego
Career Start Year 2005
Number of shared co-authors 1
Universitatsklinikum Hamburg-Eppendorf
Career Start Year 2004
Number of shared co-authors 8
IRCCS San Raffaele Scientific Institute
Career Start Year 2002
Number of shared co-authors 11
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 26
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 9
University of Illinois at Chicago
Career Start Year 1996
Number of shared co-authors 0
New York-Presbyterian Hospital
Career Start Year 1994
Number of shared co-authors 3
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Career Start Year 1993
Number of shared co-authors 35
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 6
Hospitalier Universitaire de Saint-Etienne
Career Start Year 1989
Number of shared co-authors 7
University of Toronto
Career Start Year 1989
Number of shared co-authors 43
University of Melbourne
Career Start Year 1988
Number of shared co-authors 7
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 2
Monash University
Career Start Year 1988
Number of shared co-authors 11
Amsterdam University Medical Centers, University of Amsterdam
Career Start Year 1987
Number of shared co-authors 3
Eberhard Karls University of Tubingen
Career Start Year 1984
Number of shared co-authors 7
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 40
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 3
University Hospitals Leuven
Career Start Year 1981
Number of shared co-authors 4
Royal Melbourne Hospital
Career Start Year 1974
Number of shared co-authors 14

Collaborators

The Royal Marsden Hospital NHS Foundation Trust
Co-authored papers 11
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Co-authored papers 9
University College London
Co-authored papers 8
The Institute of Cancer Research
Co-authored papers 8
The Institute of Cancer Research
Co-authored papers 8
University of Oxford, John Radcliffe Hospital
Co-authored papers 7
University of Oxford
Co-authored papers 7
The Royal Marsden NHS Foundation Trust
Co-authored papers 6
Norwich Medical School, University of East Anglia
Co-authored papers 6
Oncogenetics Team The Institute of Cancer Research London UK.
Co-authored papers 6
The Institute of Cancer Research
Co-authored papers 6
Imperial Clinical Analytics
Co-authored papers 5
Oncogenetics Team The Institute of Cancer Research London UK.
Co-authored papers 5
Institute of Cancer Research
Co-authored papers 5
University of Cambridge
Co-authored papers 5
Dorset County Hospital Foundation Trust
Co-authored papers 5
University College London
Co-authored papers 4
Wellcome Sanger Institute
Co-authored papers 4
Royal Marsden NHS Foundation Trust
Co-authored papers 4
Universidade de Santiago de Compostela
Co-authored papers 4
The Francis Crick Institute
Co-authored papers 4
University of Cambridge
Co-authored papers 4
Wellcome Sanger Institute
Co-authored papers 4
Wellcome Sanger Institute
Co-authored papers 4
Institute of Cancer Research
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Wellcome Sanger Institute
Co-authored papers 4
The Institute of Cancer Research
Co-authored papers 4
Barts Cancer Institute, Queen Mary University of London
Co-authored papers 4
University College London
Co-authored papers 4